Lindsay Fischer | Authors


Comparable Safety Profile Seen With The Addition of Darolutamide to ADT Among Patients With nmCRPC

September 16, 2021

Compared with a placebo, darolutamide demonstrated a similar safety profile in men with nonmetastatic castration-resistant prostate cancer (nmCRPC) continuing androgen-deprivation therapy, with comparable adverse event onset and occurrence rates.